Perifosine Prolongs Survival in Neuroblastoma Patients

Share this content:

(ChemotherapyAdvisor) – Perifosine shows activity against chemoresistant and radioresistant neuroblastoma, according to a team of researchers from Memorial Sloan-Kettering Cancer Center, New York, NY. This conclusion is based on an abstract entitled “Targeting the PI3K/Akt pathway: Perifosine monotherapy for resistant neuroblastoma (NB) in a phase I/Ib study,” which was presented at the Neuroblastoma Research Conference, which was held in Toronto, Ontario, Canada from June 18 to 21.

Perifosine inhibits Akt, which is aberrantly activated in NB. Phase 1 trials in children and adults with various solid tumors showed modest toxicity with dosages 50–75mg/m2/day using 50mg tablets after a loading dose of 100–200mg/m2 on day 1, noted lead author Brian Kushner, MD, of Memorial Sloan-Kettering Cancer Center. In this Phase 1/2b study, patients with evidence of NB by 123I-metaiodobenzylguanidine (MIBG) received a loading dose of oral perifosine on Day 1 followed by daily maintenance until the primary endpoint of progressive disease (PD) or excessive toxicity was reached.

The investigators reported the following anti-neuroblastoma activity in this study. Complete response (CR) was observed in one patient and a median prolonged progression-free survival of 11 (9±33) months was observed in nine patients, including three with CR in bone marrow by histology. Eight patients had early PD (<1–3 months), while other patients are progression-free with short a follow-up (<4+ months). From Day 1 of perifosine, progression-free survival is 56% (SE+11%) at 12 months. No significant toxicity was observed.

The investigators concluded: “Perifosine shows activity against chemoresistant and radioresistant NB while allowing excellent quality of life and sparing vital organs.”

Abstract (Click on link and find “POC27 on page 188)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs